BIOMAT Database Logo BIOMAT Database Logo

Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: a double-blind cross-over placebo-controlled trial. 1988

O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Service de Pharmacologie Médicale et Clinique, INSERM U 317, Faculté de Médecine, Toulouse, France.

We investigated the influence of 2 weeks of treatment with deprenyl on the acute effect of a single dose of 200 mg of L-dopa in a double-blind cross-over placebo-controlled trial in 16 parkinsonian patients with wearing-off phenomena. Deprenyl induced no significant benefit in the duration or the maximal improvement of L-dopa's effect. Moreover, deprenyl treatment did not improve the patient's motor status.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D010627 Phenethylamines A group of compounds that are derivatives of beta- aminoethylbenzene which is structurally and pharmacologically related to amphetamine. (From Merck Index, 11th ed) Phenylethylamines
D010919 Placebos Any dummy medication or treatment. Although placebos originally were medicinal preparations having no specific pharmacological activity against a targeted condition, the concept has been extended to include treatments or procedures, especially those administered to control groups in clinical trials in order to provide baseline measurements for the experimental protocol. Sham Treatment
D002986 Clinical Trials as Topic Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. Clinical Trial as Topic
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004347 Drug Interactions The action of a drug that may affect the activity, metabolism, or toxicity of another drug. Drug Interaction,Interaction, Drug,Interactions, Drug
D005260 Female Females

Related Publications

O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Selegiline (L-deprenyl) and L-dopa treatment of Parkinson's disease: a double-blind trial.
September 1994, Internal medicine (Tokyo, Japan),
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
A placebo-controlled trial of selegiline (L-deprenyl) in the treatment of tardive dyskinesia.
May 1993, Biological psychiatry,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Simvastatin Treatment Does Not Affect Serum Vitamin D Concentrations in Patients with Dyslipidemia: A Randomized Double-blind Placebo-controlled Cross-over Trial.
January 2016, International journal of preventive medicine,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Inositol treatment of Alzheimer's disease: a double blind, cross-over placebo controlled trial.
May 1996, Progress in neuro-psychopharmacology & biological psychiatry,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Double blind cross over trial with deprenyl in amyotrophic lateral sclerosis.
January 1994, Journal of neural transmission. Supplementum,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
The effect of L-dopa on young patients with simple schizophrenia, treated with neuroleptic drugs: a double-blind cross-over trial with Madopar and placebo.
October 1975, Psychopharmacologia,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Does pentoxifylline prolong the walking distance in exercised claudicants? A placebo-controlled double-blind trial.
February 1992, Angiology,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Amlodipine in patients with angina uncontrolled by atenolol. A double blind placebo controlled cross over trial.
January 1993, European journal of clinical pharmacology,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
Effects of oral L-carnitine administration in narcolepsy patients: a randomized, double-blind, cross-over and placebo-controlled trial.
January 2013, PloS one,
O Rascol, and J L Montastruc, and J M Senard, and J F Demonet, and M Simonetta, and A Rascol
A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine.
March 1986, Cephalalgia : an international journal of headache,
Copied contents to your clipboard!